Representation of Bristol-Myers Squibb Company in its $12M Investment in Compugen Ltd.

FBC represented Bristol-Myers Squibb Company (NYSE: BMY) in connection with its $12M equity investment in Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery.
The equity offering was made as a private placement of public equity (PIPE). The equity investment is being made in conjunction with a clinical trial collaboration entered into between Bristol-Myers Squibb’s and Compugen to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab), in patients with advanced solid tumors.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

For press coverage, see here and here.